^
    3d
    BARICADE-DELAY: A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (clinicaltrials.gov)
    P3, N=150, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    5d
    The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (clinicaltrials.gov)
    P=N/A, N=186, Not yet recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    hydroxychloroquine • tofacitinib
    5d
    Pharmacologic Inhibition of JAK1/2 Potentiates Aminoglycoside-Induced Ototoxicity. (PubMed, Otol Neurotol)
    JAK1 and JAK2 inhibition worsens cochlear damage in mice exposed to aminoglycosides.
    Journal
    |
    JAK1 (Janus Kinase 1) • CDH2 (Cadherin 2) • CDH3 (Cadherin 3) • CDH23 (Cadherin Related 23)
    |
    Ojjaara (momelotinib)
    5d
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=3, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    5d
    Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (clinicaltrials.gov)
    P1/2, N=20, Enrolling by invitation, National Institute of Allergy and Infectious Diseases (NIAID) | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR) • tofacitinib
    7d
    PRISM: Retifanlimab and Ruxolitinib In Solid Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, University of California, San Diego | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)
    10d
    First Report of Entrectinib as a Treatment Option for Pure Squamous Cell Carcinoma Harboring ROS1 Rearrangement: Exploring the Role of Next-Generation Sequencing in Targeted Therapy. (PubMed, Int J Mol Sci)
    This case highlights the potential of ROS1 as a therapeutic target in SCC, which has historically been considered rare, as ROS1-rearranged SCC accounts for only 0.2% according to the Foundation Medicine database. This underscores the importance of incorporating NGS into clinical practice, particularly for never smokers/light smokers or patients with advanced SCC of the lungs, to identify targetable mutations and guide personalized therapy.
    Journal • Next-generation sequencing
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 rearrangement
    |
    Rozlytrek (entrectinib)
    11d
    STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov)
    P2, N=534, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    ALK rearrangement • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib)
    11d
    Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease (clinicaltrials.gov)
    P=N/A, N=105, Completed, AbbVie | Recruiting --> Completed | N=600 --> 105
    Trial completion • Enrollment change • Adverse events
    11d
    ADMIRE: A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib (clinicaltrials.gov)
    P=N/A, N=1, Completed, AbbVie | Recruiting --> Completed | N=200 --> 1
    Trial completion • Enrollment change • Real-world evidence
    11d
    Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia. (PubMed, Leukemia)
    Using a doxycycline-inducible JAK2 knockout (KO) system, we validated JAK2 dependency in CBFA2T3::GLIS2 cell lines, observing impaired proliferation in vitro and in vivo and apoptosis induction in vitro. Both type I (ruxolitinib) and type II (CHZ868) JAK2 inhibitors showed selective in vitro activity in CBFA2T3::GLIS2-positive AML models...Both approaches converged on MAPK pathway activation as a resistance mechanism to ruxolitinib treatment. Combining ruxolitinib with MEK inhibitors showed a synergistic effect in cell lines and patient-derived xenograft (PDX) cells expressing the fusion and in vivo activity in a CBFA2T3::GLIS2 AML PDX, suggesting a potential approach to target this signaling circuitry in this poor outcome AML subtype.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2)
    |
    NRAS mutation
    |
    Jakafi (ruxolitinib) • CHZ868
    12d
    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma (clinicaltrials.gov)
    P2, N=83, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)